Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 38 entries
View as:

Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

Phase: N/A Priority: Normal
NCT ID: NCT02816970 Org: User:
Start: 02/28/14 End: 03/31/14 Due: 03/31/15

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Phase: N/A Priority: Normal
NCT ID: NCT03062423 Org: User:
Start: 10/31/16 End: 11/30/16 Due: 11/30/17

A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Phase: N/A Priority: Normal
NCT ID: NCT03005210 Org: User:
Start: 11/30/16 End: 12/31/16 Due: 12/31/17

A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Phase: N/A Priority: Normal
NCT ID: NCT02953535 Org: User:
Start: 05/31/16 End: 06/30/16 Due: 06/30/17

A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)

Phase: N/A Priority: Normal
NCT ID: NCT02480049 Org: User:
Start: 08/31/14 End: 08/31/14 Due: 08/31/15

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Phase: N/A Priority: Normal
NCT ID: NCT02529787 Org: User:
Start: 02/28/13 End: 03/31/13 Due: 03/31/14

A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )

Phase: N/A Priority: Normal
NCT ID: NCT03855306 Org: User:
Start: 06/30/18 End: 08/15/18 Due: 08/15/19

Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)

Phase: N/A Priority: Normal
NCT ID: NCT05135793 Org: User:
Start: 01/19/21 End: 03/01/21 Due: 03/01/22

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Phase: N/A Priority: Normal
NCT ID: NCT05767632 Org: User:
Start: 05/30/22 End: 10/25/22 Due: 10/25/23

A Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)

Phase: N/A Priority: Normal
NCT ID: NCT02519010 Org: User:
Start: 03/31/11 End: 03/31/11 Due: 03/31/12

Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

Phase: N/A Priority: Normal
NCT ID: NCT04657744 Org: User:
Start: 08/10/20 End: 10/20/20 Due: 10/20/21

Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)

Phase: N/A Priority: Normal
NCT ID: NCT02479854 Org: User:
Start: 04/30/14 End: 04/30/14 Due: 04/30/15

Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)

Phase: N/A Priority: Normal
NCT ID: NCT05804721 Org: User:
Start: 10/10/22 End: 12/19/22 Due: 12/19/23

Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)

Phase: N/A Priority: Normal
NCT ID: NCT04478448 Org: User:
Start: 08/13/20 End: 08/26/20 Due: 08/26/21

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

Phase: N/A Priority: Normal
NCT ID: NCT03071380 Org: User:
Start: 02/28/15 End: 03/31/15 Due: 03/31/16

A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)

Phase: N/A Priority: Normal
NCT ID: NCT02507648 Org: User:
Start: 03/31/13 End: 05/31/13 Due: 05/31/14

A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)

Phase: N/A Priority: Normal
NCT ID: NCT02477306 Org: User:
Start: 03/31/14 End: 03/31/14 Due: 03/31/15

Biosimilarity Study of IM Injection of Human Chorionic Gonadotrophin After Parenteral Administration of Treatment A TEST Product Epifasi 5000 I.U. Ampoules (EIPICO PHARMA, EGYPT) and Treatment B REFERENCE Product Pregnyl 5000 I.U. Ampoules (Baxter Pharmaceutical Solutions for Organon, USA).

Phase: N/A Priority: Normal
NCT ID: NCT04605107 Org: User:
Start: 08/30/13 End: 03/08/15 Due: 03/08/16

Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT05880056 Org: User:
Start: 08/08/24 End: 04/01/25 Due: 04/01/26

Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)

Phase: N/A Priority: Normal
NCT ID: NCT04494191 Org: User:
Start: 12/12/18 End: 02/27/19 Due: 02/27/20

Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)

Phase: N/A Priority: Normal
NCT ID: NCT04854538 Org: User:
Start: 09/17/20 End: 12/04/20 Due: 12/04/21

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Phase: N/A Priority: Normal
NCT ID: NCT05132023 Org: User:
Start: 03/26/19 End: 05/15/19 Due: 05/15/20

Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

Phase: N/A Priority: Normal
NCT ID: NCT05876585 Org: User:
Start: 06/01/25 End: 06/01/25 Due: 06/01/26

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Phase: N/A Priority: Normal
NCT ID: NCT02479867 Org: User:
Start: 03/31/14 End: 04/30/14 Due: 04/30/15

Bioequivalence Study of Esomeprazole From Stomopral 40 mg Capsules Contain Enteric Coated Pellets (Future Pharmaceuticals Industries, Egypt) and Nexium 40 mg Delayed Release Capsules (AstraZeneca Sweden, Product of France)

Phase: N/A Priority: Normal
NCT ID: NCT05038969 Org: User:
Start: 03/18/21 End: 05/28/21 Due: 05/28/22